Shkreli Thinks Raptor Pharmaceutical's Valuation Was Too Low

Shares of Raptor Pharmaceutical Corp. RPTP were trading higher by more than 20 percent Monday after the company agreed to be acquired by Horizon Pharma PLC HZNP for $800 million, or $9 per share.

Speaking as a guest on Monday's Premarket Prep, Martin Shkreli shared his take on the deal and discussed the industry as a whole.

Related Link: Raptor Jumps 20% After Horizon Pharma's $800 Million Takeover Agreement

According to Shkreli, the premium that Horizon Pharma paid to acquire Raptor was "pretty modest" and he was expecting a price tag on any acquisition deal should have been "a lot more."

As a whole, Shkreli doesn't see any "over exuberant" valuations in the space.

Shares of Raptor Pharma traded recently at $64.61, up about 8 percent on the day.

Catch our full interview below. 

PreMarket Prep is a daily trading ideas show that focuses on technical analysis and actionable short term trades. You can listen to the show live every morning from 8-9 ET here, or catch the podcast here.